The Latest News in the Life Sciences
- <b>Radius Health</b> Files IPO, Aims for $86 Million
- GlaxoSmithKline to Cut 3 Discovery Performance Units (DPUs), Will Add 4 New Units as Focus Shifts to R&D Productivity
- Pfizer Inc.'s Breast-Cancer Drug Worsens Bone Loss in Older Women
- Daiichi Sankyo, Inc. in Buyout Talks With 3 Mid-sized Companies
- Pfizer India to Sell Animal Health Division to Unit for $90 Million
- NeurogesX, Inc. Shares Plunge After FDA Staff Says Pain Patch Might Not Work
- Merck & Co., Inc. Clot Drug Meets Study Goal But Bleeding a Risk
- GlaxoSmithKline Earmarks $64.6 Million for Australian Plant; New Jobs
- Shire plc Release: Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
- Cadence Pharmaceuticals, Inc. Announces Voluntary Recall of One Lot of OFIRMEV?? (Acetaminophen) Injection
- <b>Synchroneuron</b> Completes $6 Million Series A Financing to Fund Development of a Novel Treatment for Movement Disorders
- FivePrime Therapeutics, Inc. Confirms Appointment of as CEO and Announces the Appointment of as Chairman of the Board
- Anacor Pharmaceuticals, Inc. Reports Positive Preliminary Results From Two Safety Studies Of AN2728
- Pfizer Inc., Ranbaxy Laboratories Sued Over Alleged Anti-Competitive Scheme
- Salix Pharmaceuticals, Ltd. Announces FDA Granting of Priority Review Designation for the Crofelemer NDA for Treatment of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy
- FDA Grants Genentech???s Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer
- Omeros Corporation Provides Update on Ongoing OMS302 Phase 3 Clinical Trial